Relationship between serum osteocalcin(protein produced in bone) with pancreatic beta cell function and insulin resistance in type 2 diabetic individuals
Not Applicable
- Conditions
- Health Condition 1: E11- Type 2 diabetes mellitus
- Registration Number
- CTRI/2019/01/017181
- Lead Sponsor
- KASTURBA MEDICAL COLLEGE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Type 2 Diabetes Mellitus
Exclusion Criteria
•Subjects receiving: vitamin K and its inhibitors, vitamin D and calcium, steroids, anti-epileptic drugs, Calcitonin, Bisphosphonate, estrogen,thiazolidinediones.
•Subjects having pancreatic gland dysfunction (example: pancreatitis, traumatic injury to pancreas), liver disorder (example: liver cirrhosis), musculoskeletal disorders (example: multiple myeloma, fracture), hypoparathyroidism and hyperparathyroidism, hypothyroidism and hyperthyroidism , ckd-mbd.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association of serum osteocalcin with fasting insulin levels,insulin resistance(HOMA-IR) and pancreatic beta cell function(HOMA-beta) in type 2 diabetes mellitus.Timepoint: At the time of enrollment.
- Secondary Outcome Measures
Name Time Method Secondary outcomes will be association of serum osteocalcin in type 2 diabetes mellitus subjects with: <br/ ><br>1.Fasting plasma glucose(FPG),post prandial plasma glucose(PPG),HbA1C. <br/ ><br>2.Anthropometric measurements(BMI and waist/hip ratio) and fasting lipid profile. <br/ ><br>3.Microvascular complications(retinopathy and nephropathy).Timepoint: At the time of enrollment.